Abstract
To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 973-982 |
| Number of pages | 10 |
| Journal | Kidney International |
| Volume | 41 |
| Issue number | 4 |
| State | Published - Apr 1992 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. / Spurney, Robert F.; Fan, Pang Yen; Ruiz, Phillip; Sanfilippo, Fred; Pisetsky, David S.; Coffman, Thomas M.
In: Kidney International, Vol. 41, No. 4, 04.1992, p. 973-982.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Thromboxane receptor blockade reduces renal injury in murine lupus nephritis
AU - Spurney, Robert F.
AU - Fan, Pang Yen
AU - Ruiz, Phillip
AU - Sanfilippo, Fred
AU - Pisetsky, David S.
AU - Coffman, Thomas M.
PY - 1992/4
Y1 - 1992/4
N2 - To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.
AB - To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.
UR - http://www.scopus.com/inward/record.url?scp=0026536096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026536096&partnerID=8YFLogxK
M3 - Article
C2 - 1387435
AN - SCOPUS:0026536096
VL - 41
SP - 973
EP - 982
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 4
ER -